Amarin Corp Plc (AMRN)

[Whalatane]

Montana ...going back to 2010 ...and I'll defer to JL who was posting on this ( Yahoo ) at the time .

Back in 2010 it was all about the best way to lower high / very high TG's ......not directly about EPA reducing MI's , strokes etc.
We knew high TG's were an additional risk factor beside high LDL cholesterol ...and Lovaza was an effective way to reduce high TG's ....BUT there was a risk of raising LDL cholesterol.

The suggestion was that you add a Statin .. or increase the statin dose ...to counter the risk of Lovaza elevating your LDL.

Vascepa ( AMR101 at the time ) was seen as potentially a better Omega 3 to use as less risk of LDL increase but still some TG reduction.

So there was some awareness that Vascepa ( AMR101 ) would be less likely to raise LDL cholesterol .

No one expected a decline in LDL or a neutral LDL reading in the Marine trial ...which from memory is what excited JL so much at the time ....but will let him confirm

Amarin's AMR101 Meets Pivotal Phase 3 Study Endpoints With Highly Statistically Significant Reductions in Triglycerides at 4 Gram and 2 Gram Doses in MARINE Trial With No Statistically Significant Increase in LDL-C and Safety Profile Similar to Placebo

Kiwi